Capstone Investment Advisors
ADMA icon

Capstone Investment Advisors’s ADMA Biologics ADMA Stock Holding History

Capstone Investment Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Buy
+11,174
New +$176K ﹤0.01% 1545
2025
Q3 		– Sell
-21,117
Closed -$385K – 1891
2025
Q2 		$385K Buy
+21,117
New +$431K ﹤0.01% 1271
2024
Q2 		– Sell
-16,117
Closed -$106K – 2039
2024
Q1 		$106K Buy
+16,117
New +$88.1K ﹤0.01% 2130

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Capstone Investment Advisors's ADMA Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in ADMA Biologics (ADMA) in Q1 2026: 11,174 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #1545 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in ADMA as recently as Q2 2025.

Capstone Investment Advisors first reported a position in ADMA in Q1 2024 and has held it in 3 quarters since. The position peaked at $385K in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Capstone Investment Advisors held 11,174 shares of ADMA Biologics worth $101K as of Q1 2026.
  • ADMA Biologics was a new Capstone Investment Advisors position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1545 holding.
  • Capstone Investment Advisors first reported a position in ADMA Biologics in Q1 2024 and has held it in 3 quarters since.
  • Capstone Investment Advisors's ADMA Biologics position peaked at $385K in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.